 Shares of Precision BioSciences NASDAQ:DTIL were unchanged after the company reported Q2 results.Quarterly Results Earnings per share decreased 61.54 year over year to 0.63, which missed the estimate of 0.59.Revenue of 1,078,000 decreased by 80.00 from the same period last year, which missed the estimate of 4,390,000.Looking Ahead Earnings guidance hasnt been issued by the company for now.View more earnings on DTILRevenue guidance hasnt been issued by the company for now.Technicals 52-week high: 23.6752-week low: 4.60Price action over last quarter: down 8.63Company Profile Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The companys segments include Therapeutics and Food.See more from Benzinga Earnings Scheduled For August 13, 2020C 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 